Many forms of cancer, including breast cancer, are dependent on angiogenesis, the growth of blood vessels. There is a great medical need for the development of a safe, effective, and inexpensive means of antiangiogenic therapy. One promising approach is the use of antiangiogenic peptides as the active agents. We have identified novel peptides derived from several classes of proteins that are effective at preventing angiogenesis in our preliminary studies. We have also identified other peptides able to inhibit cancer through additional mechanisms including antilymphangiogenesis and apoptosis. However, in their current form, all of these peptides have a short in vivo half-life and they are not suitable for systemic administration or for long-term action. Thus, there is a need to package, protect, and deliver these peptides in a more stable, sustained fashion. We seek to create new technology to meet this challenge and hypothesize that combinations of these peptides delivered in an engineered fashion could enable synergistic killing of breast cancer. Building on our experience with drug delivery nanoparticles, we will design an effective array of safe, biodegradable polymers for use in forming peptide-containing nanoparticles (Aim 1). These biomaterials will be used to construct nanoparticles that vary in their biophysical properties and in biological properties including tumor accumulation and peptide release. High-throughput synthesis and screening methodology will be used to select for novel nanoparticle formulations, including antiangiogenic peptide nanoparticles, highly efficient for inhibition of human endothelial cell proliferation and migration, inhibition lymphatic endothelial cell proliferation and migration, and promotion of breast cancer apoptosis. Our preliminary work shows these methods are practical and that we can synthesize new nanobiotechnology that performs superiorly to free unencapsulated peptide.
In Aim 2, lead nanoparticles containing lead anti-cancer peptides from the in vitro screens in Aim 1 will then be utilized in vivo. Angiogenesis bioreactors implanted subcutaneously in mice will be used to monitor delivery of antiangiogenic peptides by the nanoparticles. The top-performing antiangiogenic formulation will be combined with other lead anti-cancer peptides and tested in a breast cancer mouse model.
We aim to create new bionanotechnology that can safely, effectively, and relatively inexpensively treat breast cancer.
This research aims to create new bionanotechnologies that enable the efficient delivery of novel antiangiogenic, antilymphangiogenic, and pro-apoptotic peptides. The nanoparticles proposed here can facilitate the delivery of these peptides to systemically treat breast cancer.
|Bressler, Eric M; Kim, Jayoung; Shmueli, Ron B et al. (2018) Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells. J Biomed Mater Res A 106:1753-1764|
|Lee, Esak; Pandey, Niranjan B; Popel, Aleksander S (2015) Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment. Expert Rev Mol Med 17:e3|
|Bishop, Corey J; Kim, Jayoung; Green, Jordan J (2014) Biomolecule delivery to engineer the cellular microenvironment for regenerative medicine. Ann Biomed Eng 42:1557-72|
|Kim, Jayoung; Sunshine, Joel C; Green, Jordan J (2014) Differential polymer structure tunes mechanism of cellular uptake and transfection routes of poly(?-amino ester) polyplexes in human breast cancer cells. Bioconjug Chem 25:43-51|
|Lee, Esak; Lee, Seung Jae; Koskimaki, Jacob E et al. (2014) Inhibition of breast cancer growth and metastasis by a biomimetic peptide. Sci Rep 4:7139|
|Rosca, Elena V; Penet, Marie-France; Mori, Noriko et al. (2014) A biomimetic collagen derived peptide exhibits anti-angiogenic activity in triple negative breast cancer. PLoS One 9:e111901|
|Guerrero-Cázares, Hugo; Tzeng, Stephany Y; Young, Noah P et al. (2014) Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano 8:5141-53|
|Ketola, Tiia-Maaria; Hanzlíková, Martina; Leppänen, Linda et al. (2013) Independent versus cooperative binding in polyethylenimine-DNA and Poly(L-lysine)-DNA polyplexes. J Phys Chem B 117:10405-13|
|Tzeng, Stephany Y; Green, Jordan J (2013) Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. Adv Healthc Mater 2:468-80|
|Shmueli, Ron B; Bhise, Nupura S; Green, Jordan J (2013) Evaluation of polymeric gene delivery nanoparticles by nanoparticle tracking analysis and high-throughput flow cytometry. J Vis Exp :e50176|
Showing the most recent 10 out of 24 publications